文献速递妇科

妇科癌症手术中血栓形成与出血风险:系统综述与荟萃分析

Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2023-10-11

该系统综述与荟萃分析纳入188项观察性研究(398,167例患者),评估37种妇科癌症手术在不使用血栓预防措施下症状性静脉血栓栓塞症(VTE)和需再干预出血的风险。中位症状性VTE风险在13/37(35%)术式中<1%,11/37(30%)为1%-2%,13/37(35%)>2.0%;需再干预出血风险中位值在22/29(76%)术式中<1%,7/29(24%)为1%-2%。结论认为在许多妇科癌症手术中,血栓预防降低VTE的获益可能超过需再干预出血的增加。

要点

  • 不使用血栓预防时,37种妇科癌症手术中位症状性VTE风险:13种<1%,11种1%-2%,13种>2.0%。
  • 需再干预出血中位风险:22/29种术式<1%,7/29种术式1%-2%,估计范围<0.1%至1.3%。
  • VTE风险从宫颈锥切低危患者的0.1%到盆腔廓清术高危患者的33.5%不等。

核心结论

  • 在许多妇科癌症手术中,血栓预防降低VTE的获益可能超过需再干预出血的增加。
  • 在某些手术(如不伴淋巴结清扫的腹腔镜全子宫切除术)中,血栓栓塞和出血风险相似,决策取决于个体风险预测以及对VTE和出血的价值观与偏好。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、MEDLINE、Web of Science和Google Scholar的观察性研究,并检索合格研究和综述的参考文献列表。
  • 纳入标准:≥50例接受妇科癌症手术的成年患者,报告症状性肺栓塞、症状性深静脉血栓、症状性VTE、需再干预出血(包括再探查和血管栓塞)、导致输血的出血或术后血红蛋白<70 g/L中至少1项的绝对发生率。
  • 共纳入188项研究(398,167例患者),涉及37种妇科癌症手术术式。
  • 对报告的估计值按血栓预防和随访时长进行调整,使用研究的中位值确定术后4周累积发生率,按患者VTE危险因素分层,并采用GRADE方法评定证据确定性。
  • 另对血栓预防效果的随机试验进行单独检索,并开展基于网络的血栓预防实践调查。

主要发现

  • 证据确定性普遍为低至极低。
  • 不使用预防措施时,中位症状性VTE风险在13/37(35%)术式中<1%,在11/37(30%)术式中为1%-2%,在13/37(35%)术式中>2.0%。
  • VTE风险从低VTE风险患者接受宫颈锥切术的0.1%到高VTE风险患者接受盆腔廓清术的33.5%不等。
  • 需再干预出血的估计值范围为<0.1%至1.3%;中位风险在22/29(76%)术式中<1%,在7/29(24%)术式中为1%-2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to provide procedure-specific estimates of the risk of symptomatic venous thromboembolism and major bleeding in the absence of thromboprophylaxis, following gynecologic cancer surgery. DATA SOURCES: We conducted comprehensive searches on Embase, MEDLINE, Web of Science, and Google Scholar for observational studies. We also reviewed reference lists of eligible studies and review articles. We performed separate searches for randomized trials addressing effects of thromboprophylaxis and conducted a web-based survey on thromboprophylaxis practice. STUDY ELIGIBILITY CRITERIA: Observational studies enrolling ≥50 adult patients undergoing gynecologic cancer surgery procedures reporting absolute incidence for at least 1 of the following were included: symptomatic pulmonary embolism, symptomatic deep vein thrombosis, symptomatic venous thromboembolism, bleeding requiring reintervention (including reexploration and angioembolization), bleeding leading to transfusion, or postoperative hemoglobin <70 g/L. METHODS: Two reviewers independently assessed eligibility, performed data extraction, and evaluated risk of bias of eligible articles. We adjusted the reported estimates for thromboprophylaxis and length of follow-up and used the median value from studies to determine cumulative incidence at 4 weeks postsurgery stratified by patient venous thromboembolism risk factors. The GRADE approach was applied to rate evidence certainty. RESULTS: We included 188 studies (398,167 patients) reporting on 37 gynecologic cancer surgery procedures. The evidence certainty was generally low to very low. Median symptomatic venous thromboembolism risk (in the absence of prophylaxis) was <1% in 13 of 37 (35%) procedures, 1% to 2% in 11 of 37 (30%), and >2.0% in 13 of 37 (35%). The risks of venous thromboembolism varied from 0.1% in low venous thromboembolism risk patients undergoing cervical conization to 33.5% in high venous thromboembolism risk patients undergoing pelvic exenteration. Estimates of bleeding requiring reintervention varied from <0.1% to 1.3%. Median risks of bleeding requiring reintervention were <1% in 22 of 29 (76%) and 1% to 2% in 7 of 29 (24%) procedures. CONCLUSION: Venous thromboembolism reduction with thromboprophylaxis likely outweighs the increase in bleeding requiring reintervention in many gynecologic cancer procedures (eg, open surgery for ovarian cancer and pelvic exenteration). In some procedures (eg, laparoscopic total hysterectomy without lymphadenectomy), thromboembolism and bleeding risks are similar, and decisions depend on individual risk prediction and values and preferences regarding venous thromboembolism and bleeding.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lavikainen LI, Guyatt GH, Luomaranta AL, et al. Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis. Am J Obstet Gynecol. 2023. PMID: 37827272. doi:10.1016/j.ajog.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。